AR030936A1 - Derivados de (tio)urea inhibitorios de factor viia, un proceso para su preparacion y su uso - Google Patents
Derivados de (tio)urea inhibitorios de factor viia, un proceso para su preparacion y su usoInfo
- Publication number
- AR030936A1 AR030936A1 ARP010102657A ARP010102657A AR030936A1 AR 030936 A1 AR030936 A1 AR 030936A1 AR P010102657 A ARP010102657 A AR P010102657A AR P010102657 A ARP010102657 A AR P010102657A AR 030936 A1 AR030936 A1 AR 030936A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- het
- aryl
- alkoxy
- aminocarbonyl
- Prior art date
Links
- 229940012414 factor viia Drugs 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title 1
- 239000004202 carbamide Substances 0.000 title 1
- 125000001424 substituent group Chemical group 0.000 abstract 12
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 10
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 10
- 125000003545 alkoxy group Chemical group 0.000 abstract 7
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 7
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 abstract 7
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 5
- 125000005915 C6-C14 aryl group Chemical group 0.000 abstract 5
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 5
- -1 cyano, hydroxy Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- 108010054265 Factor VIIa Proteins 0.000 abstract 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 4
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 abstract 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 229910052760 oxygen Chemical group 0.000 abstract 4
- 239000001301 oxygen Chemical group 0.000 abstract 4
- 229910052717 sulfur Inorganic materials 0.000 abstract 4
- 239000011593 sulfur Substances 0.000 abstract 4
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 229920006395 saturated elastomer Polymers 0.000 abstract 3
- 125000003282 alkyl amino group Chemical group 0.000 abstract 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 2
- 125000004658 aryl carbonyl amino group Chemical group 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000004642 (C1-C12) alkoxy group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 abstract 1
- 125000005974 C6-C14 arylcarbonyl group Chemical group 0.000 abstract 1
- 125000005914 C6-C14 aryloxy group Chemical group 0.000 abstract 1
- 208000001435 Thromboembolism Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000006598 aminocarbonylamino group Chemical group 0.000 abstract 1
- 230000002785 anti-thrombosis Effects 0.000 abstract 1
- 125000005100 aryl amino carbonyl group Chemical group 0.000 abstract 1
- 125000005141 aryl amino sulfonyl group Chemical group 0.000 abstract 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 abstract 1
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 abstract 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 230000001112 coagulating effect Effects 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 230000002441 reversible effect Effects 0.000 abstract 1
- 125000006413 ring segment Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- SSGGNFYQMRDXFH-UHFFFAOYSA-N sulfanylurea Chemical compound NC(=O)NS SSGGNFYQMRDXFH-UHFFFAOYSA-N 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
- C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
- C07C2603/18—Fluorenes; Hydrogenated fluorenes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00112116A EP1162194A1 (en) | 2000-06-06 | 2000-06-06 | Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR030936A1 true AR030936A1 (es) | 2003-09-03 |
Family
ID=8168926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010102657A AR030936A1 (es) | 2000-06-06 | 2001-06-04 | Derivados de (tio)urea inhibitorios de factor viia, un proceso para su preparacion y su uso |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6743790B2 (enExample) |
| EP (2) | EP1162194A1 (enExample) |
| JP (1) | JP4809570B2 (enExample) |
| KR (1) | KR101011345B1 (enExample) |
| CN (1) | CN1208314C (enExample) |
| AR (1) | AR030936A1 (enExample) |
| AU (2) | AU7749401A (enExample) |
| BR (1) | BR0111264A (enExample) |
| CA (1) | CA2410862C (enExample) |
| CZ (1) | CZ20023963A3 (enExample) |
| DE (1) | DE60139320D1 (enExample) |
| DK (1) | DK1299354T3 (enExample) |
| EE (1) | EE200200617A (enExample) |
| ES (1) | ES2330412T3 (enExample) |
| HR (1) | HRP20020961A2 (enExample) |
| HU (1) | HUP0301631A2 (enExample) |
| IL (2) | IL153220A0 (enExample) |
| MX (1) | MXPA02009789A (enExample) |
| MY (1) | MY129363A (enExample) |
| NO (1) | NO328546B1 (enExample) |
| NZ (1) | NZ522960A (enExample) |
| PL (1) | PL359584A1 (enExample) |
| PT (1) | PT1299354E (enExample) |
| RU (1) | RU2286337C2 (enExample) |
| SK (1) | SK17032002A3 (enExample) |
| TW (1) | TWI283662B (enExample) |
| WO (1) | WO2001094301A2 (enExample) |
| YU (1) | YU89202A (enExample) |
| ZA (1) | ZA200209018B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2483228C (en) | 2002-04-27 | 2011-07-05 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Carboxamides |
| US7122580B2 (en) * | 2002-08-09 | 2006-10-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds and methods to modulate coagulation |
| AU2004249670A1 (en) * | 2003-05-20 | 2004-12-29 | Genentech, Inc. | Acylsulfamide inhibitors of factor VIIa |
| JP2007500221A (ja) * | 2003-05-20 | 2007-01-11 | ジェネンテック・インコーポレーテッド | 第ＶＩＩａ因子のベンゾフラン阻害剤 |
| US7544699B2 (en) * | 2003-08-08 | 2009-06-09 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
| WO2005014532A1 (en) * | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions and methods of use |
| US7208601B2 (en) * | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
| EP1810965A4 (en) * | 2004-10-13 | 2009-10-28 | Eisai R&D Man Co Ltd | HYDRAZIDE DERIVATIVES |
| TW200630337A (en) * | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
| US20090041747A1 (en) * | 2005-02-24 | 2009-02-12 | Novo Nordisk Health Care Ag | Compounds for Stabilizing Factor VII Polypeptide Formulations |
| US20080312161A1 (en) * | 2005-02-24 | 2008-12-18 | Anders Klarskov Petersen | Compounds For Stabilizing Factor VII Polypeptide Formulations |
| JP2008531523A (ja) * | 2005-02-24 | 2008-08-14 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | Ｖｉｉ因子ポリペプチド製剤を安定化する化合物 |
| US8633300B2 (en) | 2005-06-17 | 2014-01-21 | Novo Nordisk Healthcare Ag | Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine |
| EP2000465B1 (en) | 2006-03-24 | 2010-12-15 | Eisai R&D Management Co., Ltd. | Triazolone derivative |
| WO2007110449A1 (en) * | 2006-03-29 | 2007-10-04 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use |
| WO2007118853A1 (en) * | 2006-04-13 | 2007-10-25 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use as blockers of calcium channels |
| TW200812963A (en) * | 2006-04-13 | 2008-03-16 | Euro Celtique Sa | Benzenesulfonamide compounds and the use thereof |
| WO2008124118A1 (en) * | 2007-04-09 | 2008-10-16 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use therof |
| JPWO2009038157A1 (ja) * | 2007-09-21 | 2011-01-06 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ２，３−ジヒドロ−イミノイソインドール誘導体 |
| WO2009040659A2 (en) * | 2007-09-28 | 2009-04-02 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
| HUE040145T2 (hu) | 2011-10-26 | 2019-02-28 | Allergan Inc | N-karbamid szubsztituált aminosavak amid származékai mint formilpeptidszerû receptor 1 (FPRL1) receptormodulátorok |
| SG11201406629VA (en) * | 2012-04-16 | 2014-11-27 | Allergan Inc | (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators |
| WO2014057069A1 (en) | 2012-10-10 | 2014-04-17 | Novo Nordisk Health Care Ag | Liquid pharmaceutical composition of factor vii polypeptide |
| EP2964213B1 (en) | 2013-03-06 | 2020-11-04 | Allergan, Inc. | Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases |
| AU2014226001B2 (en) | 2013-03-06 | 2018-12-06 | Allergan, Inc. | Use of agonists of Formyl peptide receptor 2 for treating dermatological diseases |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5273982A (en) * | 1990-03-09 | 1993-12-28 | Hoffmann-La Roche Inc. | Acetic acid derivatives |
| US5506134A (en) | 1990-10-22 | 1996-04-09 | Corvas International, Inc. | Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex |
| JPH06505978A (ja) * | 1991-02-05 | 1994-07-07 | スミスクライン・ビーチャム・コーポレイション | 芳香族エステルまたはアミドを含有する抗凝集性ペプチド |
| US5833982A (en) | 1991-02-28 | 1998-11-10 | Zymogenetics, Inc. | Modified factor VII |
| US5788965A (en) | 1991-02-28 | 1998-08-04 | Novo Nordisk A/S | Modified factor VII |
| JP3387948B2 (ja) * | 1992-12-04 | 2003-03-17 | 富山化学工業株式会社 | 新規なフェニルアラニン誘導体またはその塩 |
| US5314902A (en) | 1993-01-27 | 1994-05-24 | Monsanto Company | Urea derivatives useful as platelet aggregation inhibitors |
| DE4309867A1 (de) * | 1993-03-26 | 1994-09-29 | Cassella Ag | Neue Harnstoffderivate, ihre Herstellung und Verwendung |
| GB9313268D0 (en) * | 1993-06-28 | 1993-08-11 | Zeneca Ltd | Chemical compounds |
| GB9313269D0 (en) * | 1993-06-28 | 1993-08-11 | Zeneca Ltd | Allophanic acid derivatives |
| WO1995008550A1 (en) * | 1993-09-24 | 1995-03-30 | Abbott Laboratories | Endothelin antagonists |
| WO1995011228A1 (en) * | 1993-10-19 | 1995-04-27 | Sumitomo Pharmaceuticals Co., Ltd. | 2,3-diaminopropionic acid derivative |
| US5674894A (en) * | 1995-05-15 | 1997-10-07 | G.D. Searle & Co. | Amidine derivatives useful as platelet aggregation inhibitors and vasodilators |
| AU712504B2 (en) * | 1996-01-30 | 1999-11-11 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| HUP0004200A3 (en) * | 1997-11-18 | 2001-04-28 | Dupont Pharmaceuticals Res Lab | Cyclic amine derivatives and their use as drugs |
| EP0987274A1 (en) * | 1998-09-15 | 2000-03-22 | Hoechst Marion Roussel Deutschland GmbH | Factor VIIa Inhibitors |
-
2000
- 2000-06-06 EP EP00112116A patent/EP1162194A1/en not_active Withdrawn
-
2001
- 2001-05-26 CA CA002410862A patent/CA2410862C/en not_active Expired - Fee Related
- 2001-05-26 IL IL15322001A patent/IL153220A0/xx unknown
- 2001-05-26 JP JP2002501818A patent/JP4809570B2/ja not_active Expired - Fee Related
- 2001-05-26 WO PCT/EP2001/006029 patent/WO2001094301A2/en not_active Ceased
- 2001-05-26 HR HRP20020961 patent/HRP20020961A2/hr not_active Application Discontinuation
- 2001-05-26 SK SK1703-2002A patent/SK17032002A3/sk not_active Application Discontinuation
- 2001-05-26 PT PT01955291T patent/PT1299354E/pt unknown
- 2001-05-26 PL PL01359584A patent/PL359584A1/xx not_active Application Discontinuation
- 2001-05-26 CZ CZ20023963A patent/CZ20023963A3/cs unknown
- 2001-05-26 AU AU7749401A patent/AU7749401A/xx active Pending
- 2001-05-26 YU YU89202A patent/YU89202A/sh unknown
- 2001-05-26 EP EP01955291A patent/EP1299354B1/en not_active Expired - Lifetime
- 2001-05-26 KR KR1020027016691A patent/KR101011345B1/ko not_active Expired - Fee Related
- 2001-05-26 MX MXPA02009789A patent/MXPA02009789A/es active IP Right Grant
- 2001-05-26 EE EEP200200617A patent/EE200200617A/xx unknown
- 2001-05-26 DE DE60139320T patent/DE60139320D1/de not_active Expired - Lifetime
- 2001-05-26 RU RU2002135308/04A patent/RU2286337C2/ru not_active IP Right Cessation
- 2001-05-26 HU HU0301631A patent/HUP0301631A2/hu unknown
- 2001-05-26 NZ NZ522960A patent/NZ522960A/en unknown
- 2001-05-26 AU AU2001277494A patent/AU2001277494B2/en not_active Ceased
- 2001-05-26 DK DK01955291T patent/DK1299354T3/da active
- 2001-05-26 ES ES01955291T patent/ES2330412T3/es not_active Expired - Lifetime
- 2001-05-26 BR BR0111264-3A patent/BR0111264A/pt not_active IP Right Cessation
- 2001-05-26 CN CNB018088309A patent/CN1208314C/zh not_active Expired - Fee Related
- 2001-06-04 TW TW090113412A patent/TWI283662B/zh not_active IP Right Cessation
- 2001-06-04 AR ARP010102657A patent/AR030936A1/es active IP Right Grant
- 2001-06-05 MY MYPI20012631A patent/MY129363A/en unknown
- 2001-06-06 US US09/874,318 patent/US6743790B2/en not_active Expired - Lifetime
-
2002
- 2002-11-06 ZA ZA200209018A patent/ZA200209018B/en unknown
- 2002-12-02 IL IL153220A patent/IL153220A/en not_active IP Right Cessation
- 2002-12-03 NO NO20025810A patent/NO328546B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021013135A (es) | Derivados de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2. | |
| AR029215A1 (es) | Derivados de benzazol y tautomeros de los mismos utiles en el tratamiento de desordenes en los sistemas de autoinmunidad y neuronales, uso de dichos derivados en la preparacion de composiciones farmaceuticas aplicables en el tratamiento de dichos desordenes, metodo prar inhibir la expresion y/o acti | |
| AR030553A1 (es) | Uso de derivados de tiazolilo 2,4-disustituidos para la fabricacion de un medicamento para la prevencion o el tratamiento de enfermedades mediadas a traves de citoquinas, derivados de tiazolilo 2,4-disustituidos, composiciones farmaceuticas que los comprenden, procesos para preparar dichos derivados | |
| NO308603B1 (no) | Pyrimidinylderivater som interleukininhibitorer, farmasøytisk preparat inneholdende slike derivater samt deres anvendelse | |
| EP0928789A4 (en) | 6-PHENYLTETRAHYDRO-1,3-OXAZIN-2-ON DERIVATIVES AND MEDICAL COMPOSITIONS THAT INCLUDE | |
| BR9813998A (pt) | Novos derivados de piridazina e produtos medicinais contendo os mesmos como ingredientes efetivos | |
| WO2003013484A3 (en) | N-monoacylated derivatives of o-phenylenediamines, their six membered heterocyclic analogues and their use as pharmaceutical agents | |
| ES2061471T3 (es) | Derivados de la piridina, compuestos farmaceuticos que comprenden la misma, su utilizacion para la fabricacion de medicamentos con valor terapeutico o preventivo y procedimiento para su fabricacion. | |
| NO20000077D0 (no) | Anvendelse av colchinolderivater som middel for skading av vaskulater | |
| AR020727A1 (es) | Uso de compuestos derivados 3-amino-4-aril-maleimidas para la preparacion de medicamentos para condiciones asociadas a una necesidad de inhibicion de lagsk-3, dichos compuestos, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden | |
| AR017164A1 (es) | Derivados de la benzamidina, un procedimiento para prepararlos, el empleo de los mismos para preparar un medicamento, los medicamentos y laspreparaciones farmaceuticas que contienen estos derivados de la benzamidina, y un procedimiento para obtener estas preparaciones farmaceuticas. | |
| AR048427A1 (es) | Derivados de sulfonilpirroles con actividad inhibitoria de la histona deacetilasa, composiciones farmaceuticas que los contienen y el uso de las mismas para el tratamiento de enfermedades relacionadas. | |
| NO331002B1 (no) | Tioxantinderivater og farmasoytiske preparater med tioxantinderivater | |
| YU89202A (sh) | Faktor viia inhibitorni derivati (tio)uree, njihovo dobijanje i upotreba | |
| NO953876L (no) | HIV-proteaseinhibitorer som er anvendbare for behandling av AIDS | |
| AR049711A1 (es) | Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso | |
| RU2002135308A (ru) | Производные (тио) мочевины, ингибирующие фактор viiа, их получение и применение | |
| BR0315777A (pt) | Uso de derivados de piperazina como antagonistas ccr1 | |
| BRPI0512252A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto combinado, e, processo para a preparação de um composto | |
| DE60226446D1 (de) | Zusammensetzungen zur behandlung von neoplastischen krankheiten welche einen cyanoguanidine ikk inhibitor und ein zweites antineoplastisches arzneimittel enthalten | |
| AR068695A2 (es) | Uso de un compuesto de tiazol que comprende un derivado de tiazol para la fabricacion de un medicamento para la prevencion y el tratamiento de en-fermedades causadas por la produccion anormal de citocinas y/o la acele-racion de la adhesion de neutrofilos y/o la produccion anormal de tnf- alfa | |
| NO160995C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive bis -(4-aminofenyl)-sulfoner. | |
| MX9205123A (es) | Derivados de 5-hidroxi-2-pirimidinilmetileno utiles como agentes anti-inflamatorios. | |
| DK0652874T3 (da) | 2-heterocycliske-5-hydroxy-1,3-pyrimidiner der er nyttige som antiinflammatoriske midler | |
| AR040579A1 (es) | Derivados de fenilalanina enamida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |